Adaptor CAR platform advances! On November 19, 2020, Umoja Biopharma launched with $53 million in series A financing.
Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and ICANS were reported in proportion patients and required ICU transfer. Scientists are continuously investigating new strategies to augment CAR-T cell function and simultaneously minimize treatment-related toxicities.